Outlook Therapeutics · ONS-5010 · Sep – Nov 2025
What did Outlook say came out of its September 2025 meeting with the FDA?
A “productive discussion” and a plan to resubmit, then a resubmission it believed would resolve the outstanding issue. After the second letter it said it had understood the two sides were aligned.
EphemerisX Research · Published · 5 source documents · 1 min read
Short answer
Outlook described the September 2025 Type A meeting as productive and resubmitted in November after receiving the minutes, saying it believed the resubmission would resolve the outstanding issue. In February 2026, after the second letter, it said it had understood it was aligned with the FDA on the requirements, and that the letter was unexpected.
What the evidence shows
September 29, 2025: the company has completed the Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025
8-K · Sep 29, 2025. The CEO: We had a productive discussion with the FDA
8-K · Sep 29, 2025.
November 3, 2025: it re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, after receiving the official minutes from the FDA Type A meeting conducted in September 2025
8-K · Nov 3, 2025. The CEO: we believe this resubmission will resolve the outstanding issue highlighted in the Complete Response Letter (CRL) we received in August 2025
8-K · Nov 3, 2025. The November 3, 2025 press release on the resubmission does not describe its contents: it does not mention mechanistic, natural history or pharmacodynamic data, or confirmatory evidence. 8-K · searched
The December 10-K says only that at the meeting we received feedback on resubmitting the BLA
10-K · Dec 19, 2025.
February 11, 2026: Based on prior discussions with the FDA in September 2025, during which Outlook Therapeutics understood that it had aligned with FDA on the requirements for resubmission of the BLA, the issuance of an additional CRL was unexpected
8-K · Feb 11, 2026. Six days later the CEO said the discussions have confirmed alignment on CMC, safety, and the positive results from NORSE TWO
8-K · Feb 17, 2026.
Not in this record: the minutes of the September 2025 meeting. What the December letter said: What changed between the FDA's August and December 2025 letters?
Follow the thread
- What changed between the FDA's August and December 2025 letters?“Will resolve the outstanding issue”
- What happened after the FDA's December 2025 letter?“Aligned”, then “unexpected”
- Why do Outlook's filings give different dates for the FDA's letters?“Dated August 27, 2025”
The documents, by date
The passages quoted
Outlook Therapeutics Form 8-K, filed September 29, 2025
today announced that it has completed the Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. Based on the discussion with the FDA, Outlook Therapeutics expects to resubmit its BLA before the end of calendar year 2025, after reviewing the agency’s feedback and meeting minutes.Open at the source →
Outlook Therapeutics Form 8-K, filed September 29, 2025
We had a productive discussion with the FDA. Based on our meeting, and pending receipt of the agency’s written minutes, we plan to resubmit the BLA later this year.Open at the source →
Outlook Therapeutics Form 8-K, filed November 3, 2025
The November 3, 2025 press release on the resubmission does not describe its contents: it does not mention mechanistic, natural history or pharmacodynamic data, or confirmatory evidence.
Open the document →Outlook Therapeutics Form 8-K, filed November 3, 2025
Based on our productive meeting with the FDA in September, we believe this resubmission will resolve the outstanding issue highlighted in the Complete Response Letter (CRL) we received in August 2025.Open at the source →
Outlook Therapeutics Form 8-K, filed November 3, 2025
today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, after receiving the official minutes from the FDA Type A meeting conducted in September 2025.Open at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
In September 2025, we conducted a Type A meeting with the FDA at which we received feedback on resubmitting the BLA. We subsequently resubmitted the ONS-5010/LYTENAVA BLA and have received a Prescription Drug User Fee Act, or PDUFA, goal date of December 31, 2025 for a decision by the FDA;Open at the source →
Outlook Therapeutics Form 8-K, filed February 11, 2026
The CRL identified a single deficiency based on a purported lack of substantial evidence of effectiveness, and recommended submission of additional confirmatory evidence. Outlook Therapeutics believes this determination is inconsistent with the totality of evidence submitted in the BLA, including data from an adequate and well-controlled study and confirmatory evidence of effectiveness. Based on prior discussions with the FDA in September 2025, during which Outlook Therapeutics understood that it had aligned with FDA on the requirements for resubmission of the BLA, the issuance of an additional CRL was unexpected. Prior to submitting the Type A meeting request, Outlook Therapeutics conducted informal meetings with the FDA to discuss the CRL.Open at the source →
Outlook Therapeutics Form 8-K, filed February 17, 2026
Our ongoing discussions with the FDA beginning in September 2025 have confirmed alignment on CMC, safety, and the positive results from NORSE TWO, and we look forward to constructive discussions with the FDA as we seek guidance on confirmatory evidence that will withstand current dynamics.”Open at the source →